Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828619 | 0.73 | KMT2A (0.57) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| SCHEMBL11882632 | 0.73 | KMT2A (0.57) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| SCHEMBL6598982 | 0.72 | — | — | |
| SCHEMBL7611308 | 0.71 | KMT2A (0.55) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| Hydrochloric Acid SCHEMBL738023 | 0.71 | KMT2A (0.55) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| Bromide SCHEMBL7400039 | 0.71 | KMT2A (0.55) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| SCHEMBL5571659 | 0.70 | PARP1 (0.47) | PARP1KMT2AASAH1MEN1 | |
| Carbamic Acid SCHEMBL10888970 | 0.70 | SMN1; SMN2 (0.56) | KMT2ASMN1; SMN2ASAH1HTTMEN1 | |
| SCHEMBL1823973 | 0.68 | GRM5 (0.34) | SMN1; SMN2HTT | |
| SCHEMBL6526827 | 0.68 | KMT2A (0.35) | PARP1KMT2ASMN1; SMN2ASAH1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | LEE JUSTIN C (US) | 2016-02-18 | — | — | US | claimed |
| WO-2014169087-A2 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-16 | — | — | WO | claimed |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | LEE JUSTIN C (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014169087-A2 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-16 | — | — | WO | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | PARP1 1606/4885ELANE 2819/4885KMT2A 292/4885 |
| US-20160045617-A1 | TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY | CELF2, SMN1; SMN2, GRM8 | PARP1 4392/4885ELANE 1423/4885KMT2A 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.